Get the Finder app 🥳

Track your credit score

Free

How to buy Takeda Pharmaceutical shares | $16.67

Own Takeda Pharmaceutical shares in just a few minutes.

Posted

Fact checked
Picture not described

We’re committed to our readers and editorial independence. We don’t compare all products in the market and may receive compensation when we refer you to our partners, but this does not influence our opinions or reviews. Learn more about Finder.

Takeda Pharmaceutical Company Limited is a drug manufacturers—specialty & generic business with stocks listed in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$16.67 – the same closing value as a week prior.

How to buy shares in Takeda Pharmaceutical

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Takeda Pharmaceutical. Find the share by name or ticker symbol: TAK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Takeda Pharmaceutical reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$16.67, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Takeda Pharmaceutical, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Takeda Pharmaceutical. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Takeda Pharmaceutical's share price?

Since the stock market crash in March caused by coronavirus, Takeda Pharmaceutical's share price has had significant negative movement.

Its last market close was US$16.67, which is 11.28% down on its pre-crash value of US$18.79 and 34.11% up on the lowest point reached during the March crash when the shares fell as low as US$12.43.

If you had bought US$1,000 worth of Takeda Pharmaceutical shares at the start of February 2020, those shares would have been worth US$689.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$861.01.

Takeda Pharmaceutical share price

Use our graph to track the performance of TAK stocks over time.

Takeda Pharmaceutical shares at a glance

Information last updated 2020-10-20.
Latest market closeUSD$16.67
52-week rangeUSD$12.43 - USD$20.93
50-day moving average USD$18.0149
200-day moving average USD$18.0602
Target priceUSD$23.72
PE ratio 46.6045
Dividend yield USD$0.84 (5%)
Earnings per share (TTM) USD$0.8115

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

  • $0 brokerage for US stocks
  • Trades starting from $50
  • Fractional shares
  • Copy top traders
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

Is it a good time to buy Takeda Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Takeda Pharmaceutical price performance over time

Historical closes compared with the close of $16.67 on 2020-10-16

1 week (2020-10-22) 0.18%
1 month (2020-09-29) -8.10%
3 months (2020-07-29) -8.81%
6 months (2020-04-29) -10.62%
1 year (2019-10-29) -5.93%
2 years (2018-10-29) -16.90%
3 years (2017-10-27) -41.07%
5 years (2015-10-29) -32.56%

Is Takeda Pharmaceutical under- or over-valued?

Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Takeda Pharmaceutical's P/E ratio

Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Takeda Pharmaceutical shares trade at around 47x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Takeda Pharmaceutical's PEG ratio

Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1821. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Takeda Pharmaceutical financials

Gross profit TTM US$2,201.5 billion
Return on assets TTM 1.45%
Return on equity TTM 2.5%
Profit margin 3.69%
Book value 12.5505
Market capitalisation US$52.6 billion

TTM: trailing 12 months

Shorting Takeda Pharmaceutical shares

There are currently 3.5 million Takeda Pharmaceutical shares held short by investors – that's known as Takeda Pharmaceutical's "short interest". This figure is 26% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting Takeda Pharmaceutical shares can be evaluated.

Takeda Pharmaceutical's "short interest ratio" (SIR)

Takeda Pharmaceutical's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical shares currently shorted divided by the average quantity of Takeda Pharmaceutical shares traded daily (recently around 1.1 million). Takeda Pharmaceutical's SIR currently stands at 3.13. In other words for every 100,000 Takeda Pharmaceutical shares traded daily on the market, roughly 3130 shares are currently held short.

However Takeda Pharmaceutical's short interest can also be evaluated against the total number of Takeda Pharmaceutical shares, or, against the total number of tradable Takeda Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical.

Find out more about how you can short Takeda Pharmaceutical stock.

Takeda Pharmaceutical share dividends

1%

Dividend payout ratio: 1.39% of net profits

Recently Takeda Pharmaceutical has paid out, on average, around 1.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical shareholders could enjoy a 5% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical's case, that would currently equate to about $0.84 per share.

While Takeda Pharmaceutical's payout ratio might seem low, this can signify that Takeda Pharmaceutical is investing more in its future growth.

Takeda Pharmaceutical's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 March 2020 (the "ex-dividend date").

Takeda Pharmaceutical share price volatility

Over the last 12 months, Takeda Pharmaceutical's shares have ranged in value from as little as US$12.43 up to US$20.93. A popular way to gauge a stock's volatility is its "beta".

TAK.US volatility(beta: 1.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical's is 1.1041. This would suggest that Takeda Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Takeda Pharmaceutical overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site